The Center for Biologics Evaluation and Research moved toward greater manufacturing flexibility and stricter evaluation of clinical evidence with cell and gene therapies. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
